98%
921
2 minutes
20
Background: Multi-limb amputations are extremely rare and devastating injuries, particularly in the context of civilian disasters. The 2023 Türkiye earthquake resulted in a significant number of complex traumatic injuries, including multiple limb amputations. This study aims to investigate early mortality, surgical complications, and functional outcomes at two-year follow-up in civilian patients who underwent two or more limb amputations following the disaster.
Methods: A retrospective analysis was conducted on 22 patients who sustained multiple limb amputations after the earthquake. Demographic data, amputation levels, surgical interventions, complications, and outcomes at two-year follow-up were recorded. The primary outcomes were mortality, the number and type of reoperations, and functional recovery at two years.
Results: Among the cohort, two-limb amputations were performed in 17 patients, three-limb amputations in 4 patients, and four-limb amputation in 1 patient. Twenty patients required at least one additional surgical procedure during hospitalization, most commonly surgical debridement for soft tissue infection. Eight patients died, of whom five had undergone amputation of three or more limbs. Sepsis was the leading cause of death. Follow-up data at two years were available for 14 survivors. Of these, only 3 patients were able to ambulate independently using prosthetic devices. Phantom limb pain was reported in 6 patients, and all received medical management. The average hospital stay exceeded 80 days in patients with bilateral amputations.
Conclusions: This study presents one of the largest case series of multi-limb amputees following a civilian earthquake. The findings highlight the high rate of reoperation, substantial mortality, and limited functional recovery at two-year follow-up in this population. Early multidisciplinary rehabilitation strategies should be prioritized to improve outcomes in future mass-casualty settings.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12398020 | PMC |
http://dx.doi.org/10.1186/s13018-025-06231-y | DOI Listing |
Aim To compare the results of primary percutaneous coronary intervention (PCI) for non-ST-segment elevation acute coronary syndrome (NSTE-ACS) in patients who recently recovered from COVID-19 with those not previously infected with SARS-CoV-2; to establish prognostic criteria for PCI complications, including stent thrombosis and restenosis (ST and SR) and progression of ischemic heart disease, and to determine ways to prevent them.Material and methods In 2021, middle-aged patients admitted to the Baku Central Clinical Hospital with a diagnosis of acute coronary syndrome who underwent urgent myocardial revascularization using percutaneous balloon angioplasty of the occluded coronary artery (CA) with implantation of a second-generation intracoronary drug-eluting stent were divided into two observation groups: the main group of 123 patients who had COVID-19 in the previous 6 months, and the control group of 112 patients who were not previously infected with SARS-CoV-2. The immediate results of PCI were assessed according to the TIMI scale; complications were assessed both clinically, by the incidence of severe complications (major adverse cardiovascular events, MACE), and angiographically, by the incidence of early and late ST and SR, and de novo stenosis that developed during the two-year observation period.
View Article and Find Full Text PDFEClinicalMedicine
October 2025
Department of Cardiology, Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Background: The benefits of physiology-guided management in acute coronary syndrome (ACS) remain inconclusive due to limited evidence. In our FAVOR III China trial, a quantitative flow ratio (QFR)-based physiology-guided strategy versus standard angiography guidance improved the 1-year primary outcome among participants with coronary artery disease (CAD). We aimed to investigate, in a prespecified analysis, the outcomes of QFR-based physiological guidance in the FAVOR III China participants with low-risk ACS.
View Article and Find Full Text PDFOral Dis
September 2025
Clinical Department, Radiation Oncology Unit, National Center for Oncological Hadrontherapy (CNAO), Pavia, Italy.
Aim: To evaluate the outcomes of combining carbon ion radiotherapy boost (CIRTb) with photons (Ph) or protons (PT) for locally advanced salivary gland and sinonasal cancers (SGCs and SNCs).
Materials And Methods: Sixty-nine patients with SGCs and SNCs received CIRTb to high-risk CTV and Ph or PT to low-risk CTV (LR-CTV) from October 2014 to September 2022. Two-year local relapse-free survival (LRFS) was analyzed with Kaplan-Meier.
Sleep Adv
August 2025
Division of Public Health, Department of Family and Preventive Medicine, University of Utah, 303 Chipeta Way, Salt Lake City, UT 84013, United States of America.
Individuals with mild cognitive impairment (MCI) demonstrate cognitive decline without major functional impairment and are at increased risk for developing Alzheimer's disease and related dementias (ADRD). Sleep and biobehavioral rhythm disturbances (disruptions in 24-h oscillations in physiology and behavior, including rest-activity patterns and mealtimes) are more than twice as common among patients with MCI than cognitively intact older adults. Importantly, the consequences of sleep and biobehavioral rhythm disruption in MCI extend beyond the patient, also profoundly affecting the spouse/partner.
View Article and Find Full Text PDFBlood
September 2025
University, Hospital and Faculty of Medicine, Hradec Králové, Czech Republic, Hradec Králové, Czech Republic.
Epcoritamab is a subcutaneous CD3xCD20 bispecific antibody approved as monotherapy for relapsed/refractory (R/R) follicular lymphoma (FL). We evaluated fixed-duration epcoritamab with rituximab plus lenalidomide (R2) in R/R FL in arm 2 of EPCORE® NHL-2 (phase 1b/2; NCT04663347). Patients received epcoritamab (2 step-up doses, then 48-mg full doses) for up to 2 years and R2 for up to 12 cycles (28 days/cycle).
View Article and Find Full Text PDF